Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?

SIMPLE SUMMARY: Checkpoint inhibitors and anti-angiogenic therapies are treatments that slow the progression of renal cell carcinoma, the most common type of kidney cancer. Checkpoint inhibitors and anti-angiogenic therapies work in different ways. Checkpoint inhibitors help to prevent tumors from h...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonasch, Eric, Atkins, Michael B., Chowdhury, Simon, Mainwaring, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833428/
https://www.ncbi.nlm.nih.gov/pubmed/35158916
http://dx.doi.org/10.3390/cancers14030644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833428/
https://www.ncbi.nlm.nih.gov/pubmed/35158916
http://dx.doi.org/10.3390/cancers14030644

Ejemplares similares